Vandria SA is a biopharmaceutical spin-off from Amazentis SA and was incorporated in Switzerland in 2021. The company discovers and develops novel small molecules that can effectively induce mitophagy to treat age-related and chronic diseases. Vandria is in the the IND-enabling stage with two lead candidates that have shown highly promising results in vitro and in vivo. The first clinical trials are expected to begin in Q2-2024 Through a unique drug discovery engine and a dedicated R&D team, we have developed and patented a range of novel small molecules that specifically can target the brain, muscle tissue, and other tissues. Vandria is seeking investors to complete its investor syndicate for a Series A financing round which will be concluded in Q3-2023. The disease focus is: CNS: Mild Cognitive Impairment, ALS Muscle: Sporadic Inclusion Body Myositis, Sarcopenia Other: Inflammatory diseases, immuno-oncology Vandria is open to discuss partnering opportunities with biotech and pharmaceutical companies, both in relation to our mitophagy inducer pipeline and our novel ferroptosis inhibitors. | x
Swistor
Swistor SA is a Cleantech startup specializing in the development, manufacturing, and sale of innovative ultra-fast charging devices that combine high energy storage capabilities with high-power delivery capabilities, to enable the next generation of energy storage devices and provide a long lasting and non-toxic and safe solution.
Perovskia Solar AG
PEROVSKIA SOLAR AG is a Swiss cleantech startup that provides digitally printed customizable solar cells to OEMs. he solar cells are tailored to seamlessly integrate into electronic devices & sensors. Our versatile technology offers breakthrough performance at disruptive costs. Our cells operate efficiently even in low-light conditions.
PDC Therapeutics
PDC Therapeutics is a nanomedicines biotech company, developing targeted Polymer Drug Conjugates which provide cancer patients with an optimal therapeutic index. We are exploiting the proprietary and clinically validated platform technology of parent company RS Research, a clinical stage academic spin-off which has discovered a pioneering class of nanocarriers with a versatile targeting capability. Our nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development. We manufacture our products at our own GMP certificated production facility for clinical batch lyophilized oncology drugs. We look forward to leveraging our Sagitta™ nanocarrier platforms to enrich partners’ pipelines by developing cutting-edge targeted therapies. | PDC Therapeutics is a biotechnology start-up developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. The most advanced candidate utilizing a Sagitta® platform is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development. RS Research also has a GMP-certified production facility for clinical batch drug candidates. We look forward to leveraging our Sagitta® nanocarrier platforms to enrich partners’ pipelines by developing cutting-edge targeted therapies. | Unlocking the Potential of Targeted Therapies with No Compromise, with Clinically Validated Drug Delivery Technologies: PDC Therapeutics is a biotechnology start-up, founded by 2024 EIC European Prize for Women Innovators winner Prof. Rana Sanyal and Sena Nomak, developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. PDC Therapeutics’ proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. -The most advanced candidate utilizing a Sagitta® platform is developed by RS Research, which has a nanomedicine pipeline in various stages of preclinical and clinical development. RS Research also has a GMP-certified production facility for clinical batch drug candidates. We look forward to leveraging our Sagitta® nanocarrier platforms to enrich partners’ pipelines by developing cutting-edge targeted therapies. -Technology Platform: Sagitta®: Clinically validated Sagitta® biodegradable conjugation platforms are discovered to reinforce ideal performances in terms of the therapeutic index, pharmacokinetics and manufacturability that are experimentally proven to be translatable across species. Our Sagitta® nanocarriers are compatible with a broad spectrum of technology platforms used in conjugated drugs, including a wide range of targeting ligands/mAbs and linkers. Fine-tuning the selection of cleavable linkers enables controlled release of the payloads, improving the tolerability profile. All Sagitta® platforms are available for licensing and co-development opportunities. -Sagitta® Bir is a version of the platform with a water-soluble and biocompatible polymer backbone that enables the covalent linkage of multiple payload molecules. The lead candidate in RS Research’s pipeline (open for out-licensing) based on Sagitta® Bir has progressed to the dose-expansion phase in the ongoing Phase I clinical trial in the oncology domain. -Sagitta® Dui is another version of the platform, which is synthesized as a block copolymer and forms a micelle structure upon contact with water. Importantly, it enables a dual payload capacity such that while one payload is covalently linked, another payload is encapsulated in the micelle, yielding an increased loading capacity of over 50% by weight and a synergistic effect. The most advanced molecule in RS Research’s pipeline based on Sagitta® Dui is currently in the preclinical phase. Compared to Antibody-Drug Conjugates (ADCs), Sagitta® platforms offer distinct advantages by enabling the attachment of a significantly larger number of drugs per molecule. Sagitta® Bir boasts a Drug-to-Antibody Ratio (DAR) exceeding 30, while ng to the end of dose-finding activities in the ongoing Phase I clinical trial in the oncology domain. Sagitta® Dui achieves a DAR surpassing 400. This expanded payload capacity not only broadens the therapeutic possibilities but also allows for the utilization of less toxic drugs that are typically unsuitable for ADCs. -Sagitta Radix is a targeted radiopharmaceutical delivery platform capable of binding radionuclides such as gallium (Ga), zirconium (Zr), actinium (Ac), or lutetium (Lu), enhancing its utility in both therapeutic and diagnostic applications. Sagitta Radix’s design allows for precise targeting of disease sites via monoclonal antibodies (mAbs) or peptides, aiding with the decision-making process for theranostic applications. This platform holds promise for developing next-generation theranostics, leveraging its unique ability to bind and deliver radionuclides to specific cellular targets. -Why Sagitta®? Advantages Over ADCs and Conventional Platforms: • Expanded Payload Capacity: Deliver significantly higher drug amounts per carrier molecule. • Modular Targeting: Compatible with a wide range of ligands, including mAbs and peptides. • Controlled Release: Cleavable linkers allow for customized drug release kinetics. • Biodegradable Polymers: Engineered for safety, scalability and regulatory compliance. • Clinically Validated: Ongoing human trials with lead candidates demonstrate platform translatability across species and therapeutic areas. -Lead Asset: RS-0139: RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the remarkable therapeutic index offered by Sagitta® technology. RS-0139 was developed benefiting the remarkable therapeutic index offered by Sagitta® technology. It has progressed to the dose-expansion phase in the ongoing Phase Ib clinical trial in the oncology domain. RS-0139 leverages PDC Therapeutics’ proprietary Sagitta® Bir nanoparticles platform. It delivers the cytotoxic payload, targeting integrin receptors. Preclinical studies have consistently confirmed the improved therapeutic index of the payload delivered with our technology. The efficacy of RS-0139 also shows significant improvement in various xenograft models in oncology. -For more: RS-0139 Preclinical & Clinical Data: https://pdcbio.com/2023/rs-0139-a-novel-tumor-targeted-delivery-of-docetaxel/ Phase Ia/Ib Study Summary: https://pdcbio.com/2022/phase-ia-ib-study-of-rs-0139/ -Partnering & Business Development: PDC Therapeutics is actively pursuing co-development, licensing and out-licensing partnerships with biotech and pharmaceutical companies seeking: • Solutions for rescuing shelved or challenging compounds • New modalities for targeted delivery in oncology and beyond • Expansion into radiotheranostics or dual payload strategies • Platform technologies with established IP and clinical proof-of-concept We are particularly open to partnerships for therapeutic areas requiring high precision delivery, reduced off-target toxicity, or where existing modalities like ADCs have failed to meet expectations. -IP & Regulatory Readiness: The Sagitta® platforms are protected by two patent families filed in 2018 worldwide. Our technologies are supported by a GMP-certified manufacturing facility operated by RS Research, ensuring scalability and clinical readiness for our partners’ development programs. -Let’s Collaborate: At PDC Therapeutics, we believe that advanced delivery systems like Sagitta® will define the future of precision medicine. Whether you’re seeking a delivery solution to revive a stalled asset or a co-development partner to power your pipeline, we’re ready to collaborate. Visit us at the BIO International Convention Contact: info@pdcbio.com Website: pdcbio.com LinkedIn: PDC Therapeutics: https://www.linkedin.com/company/pdc-bio Twitter: @PDCTherapeutics: https://x.com/PDCTherapeutics
NewBiologix
NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. NewBiologix is committed to improve the generation and production of viral vectors used in gene and cell therapies by combining innovative and proprietary bioinformatics platform with advanced R&D experimentation. Next-generation sequencing (NGS)-based genome characterization will be used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through a combination of exceptionally in-depth datasets, sophisticated genomic analyses, and advanced R&D experimentation. NewBiologix’ technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of products. With a strong Series A financing and an experienced start-up team established, NewBiologix anticipates cell line prototypes will be ready for beta testing with key collaborators by 2024 with the goal of commercially available viral production cell line lines by 2025. | NewBiologix is a technology innovation company developing proprietary platforms for the improved production of viral vectors used in gene and cell therapies. The company offers best-in-class rAAV variant screening, proprietary engineered HEK293 cell line programs, and next-generation sequencing (NGS) services including PacBio, Illumina, Nanopore, and Bionano. Our suite of technologies aims to help biopharmaceutical companies develop transformative gene therapies faster, safer, and at scale. | NewBiologix SA is a biotechnology company developing Swiss-engineered solutions for gene and cell therapy production. Specializing in cell line engineering, the company offers advanced cell lines and a genomic analytical platform, including the Xcell Engineered HEK293 Cell Line, custom high-quality AAV production, and cellular and viral genomic characterization with integrated bioinformatics. Our expertise enables partners to develop and scale gene therapies faster, while ensuring they are safer and more reliable.
Navori Labs
Navori Digital Signage Software is a highly scalable enterprise-grade digital signage solution with multiplatform support. The software features an open architecture and a proprietary API for third-party system integration. Navori is available in the cloud and on-premises. It includes three modules: Navori Server with multi-tenancy and multi-level content management. Navori Content Manager is an intuitive HTML5-based user interface, and Navori Player, the most powerful and efficient media player software available for Windows, Android, ChromeOS and System-on-Chip (SoC) devices. Each Navori Player version shares the same professional features, including multi-layer templates and native content playback. Additionally, Navori supports DooH programmatic advertising and AI-computer vision analytics, including footfall, dwell time, and vehicle metrics. | Navori Labs is a global leader in intelligent digital signage software, shaping the future of on-screen communication. Founded in 1998 and headquartered in Switzerland, the company brings more than 28 years of continuous innovation and precision engineering to the digital signage industry. Navori delivers an enterprise-grade platform that connects content, data, and real-world context to create audience-first, measurable on-screen experiences. Built for performance, scalability, and security, the software supports mission-critical deployments and meets enterprise compliance standards, including SOC 2 Type II and ISO/IEC 27001. As the world’s leading channel-only digital signage independent software vendor, Navori operates through a 100% channel-first model, empowering resellers and system integrators worldwide. With over 1.5 million licenses deployed across more than 125 countries and support for multiple languages, Navori’s open architecture integrates seamlessly with existing systems and hardware. Through automation, AI-driven intelligence, and real-time data integration, Navori Labs enables organizations to communicate smarter, scale confidently, and deliver measurable outcomes in the physical world. | Navori Labs has been a global leader in digital signage software for 28 years. Every day, we wake up with one mission in mind: to innovate top-quality signage solutions for all businesses. From restaurants and public transportation to schools and hospitals, we provide tailored solutions for diverse industries. Efficiency and ease of use define our approach. Developed in-house by a team of highly qualified engineers, our multi-platform digital signage software empowers users with professional-grade tools for dynamic content creation and real-time data management. Our advanced AI-enhanced analytics provide actionable insights into audience behaviour. Reliability, security, and performance are our top priorities. With SOC2 certification, we ensure trust and compliance, offering both cloud and on-premise products for government and enterprise use.
Nagi Bioscience
Nagi Bioscience is a pioneering high-tech Swiss company developing NextGen laboratory equipment to unlock the full potential of alternatives to animal testing with our patented Organism-on-Chip technology for high-content screening of drugs, chemicals, and other substances. Our technologies are accelerating drug development pipelines and introducing new toxicology testing standards revolutionizing pharmaceutical, biotech, food and nutrition, agro-chemical, cosmetic and animal health industries.
Mirava Bio
Mirava Bio is a BioCommercial partner supporting emerging rare disease biotechs with no presence in Europe in defining de-risked, cross-functional and flexible go-to-market strategies—and staying alongside them to ensure successful execution and product launch.
Limula
Cell and gene therapy (CGT) manufacturing is outdated, fragmented, and unable to scale. Manual, labor-intensive processes developed in academic labs lead to high costs, long tech transfer timelines, and regulatory hurdles, causing 30 to 40 percent of projects to fail even when therapies are clinically effective. In 2023, only 2 percent of the 500,000 patients eligible for approved CAR-T therapies received treatment, underscoring the urgent need for scalable, robust manufacturing solutions. Limula is addressing this challenge. Based in Lausanne, Switzerland, the company is on a mission to make highly personalised CGT products accessible to patients in need, at reasonable cost, wherever they are. Limula offers a smart platform, LimONE, that enables end-to-end automation for on-demand, scalable manufacturing of personalised cell therapies at the point of care. Its unique, proprietary technology consolidates every step of the production process into a single instrument, significantly reducing costs by minimising skilled manual labour, equipment, and infrastructure requirements.